Skip to main content

Table 3 Inflammatory biomarkers in relationship to clinical features (longitudinal studies)

From: Inflammatory biomarkers in patients with sciatica: a systematic review

Study Age (yr) Duration (weeks) Source Technique Substance Clin O Ass
Schistad [15] 41.3 (10) 20.3 (19.9) serum ELISA Il-6 VAS B = 0,64a
Sturmer [23] 44.8 (12.4) acuteb serum latex agl hsCRP VAS > 4 aOR = 3,4c
Andrade [24] 49 N NP Biopsy mRNA qPCR TNFa VAS r = 0,65
AF Biopsy mRNA qPCR TNFa VAS r = 0,06
LF Biopsy mRNA qPCR TNFa VAS r = 0,29
Andrade [25] 41 13–26 NP Biopsy mRNA qPCR IL-6 VAS r = 0,23
NP Biopsy mRNA qPCR IL-1b VAS r = 0,05
NP Biopsy mRNA qPCR IL-6 VAS r = −0,11
NP Biopsy mRNA qPCR IL-1b VAS r = 0,03
Pedersen [26] 39.3 (18–58) 32.3 + − 4.5 serum ELISA IL-6 VAS F(1.0, 118) = 9,7
serum ELISA IL-8 VAS F(1.0, 118,0) = 6,9
Wang [27] 37 + −13.3)d 48 (+ − 29) serum ELISA IL-6 ODI r = 0,394
serum ELISA TNFa ODI r = 0,629
serum ELISA IL-10 ODI r = 0,415
serum ELISA IL-8 ODI r = −0,133
Moen [28] 40 (9) > 8 serum PEA inflammation score VAS positive Linear discriminant analysis
Zu [29] 34.0 + −12.3e 48 (+ − 29)c serum ELISA TNFa ODI + VAS > 3 r = 0,2
serum ELISA TNFa ODI + VAS < 3 r = 0,37
serum ELISA IL-4 ODI + VAS > 3 r = 0,09
serum ELISA IL-4 ODI + VAS < 3 r = 0,08
Chen [30] 51.3 + −24.4 N NP biopsy Western blot IL-21 VAS r = 0.834
  1. AF annulus fibrosus, aOR adjusted Odds Ratio, Ass association, Clin O clinical outcome, LF ligamentum flavum, ELISA enzyme linked immune assay, hsCRP high sensitive c-reactive protein, Il interleukin, latex agl latex agglutination, mRNA messenger RNA, N unknown, NP nucleus pulposus, ODI Oswesty Disability Index, PEA proximal extension assay, TNF tumour necrosis factor alpha, Yr years, VAS visual analogue scale
  2. amultivariate regression analysis
  3. bno definition
  4. cadjusted for age, sex, smoking, alcohol, body mass, use of diuretics and analgetic drugs and steroid injections during the previous 24 h
  5. dhigh pain group (VAS > 3)
  6. esubgroup ruptured AF